药明康德连续三年入选富时罗素社会责任指数系列 | Bilingual News

上海，2025年8月6日 – 药明康德今日宣布，公司连续第三年入选“富时罗素社会责任指数系列”（FTSE4Good Index Series）。这一认可充分彰显了公司对推动可持续发展的坚定承诺，以及为构建一个更健康、更可持续的未来所做出的努力。

富时罗素社会责任指数系列由全球指数和数据提供商富时罗素（FTSE Russell）设立，旨在衡量具有特定环境、社会责任和治理（ESG）实践的公司的表现，只有符合各项标准的公司才会被纳入富时罗素社会责任指数系列。在本次评估周期中，药明康德在治理、反腐败和劳工标准三项主题均获满分5分，体现了公司在可持续管理方面的卓越表现。

“我们很荣幸再次入选富时罗素社会责任指数系列，这充分体现了资本市场对药明康德在可持续管理实践方面的信心与认可。”药明康德联席首席执行官、ESG委员会主席杨青博士表示，“药明康德将继续推动可持续发展战略，履行企业社会责任，助力客户加速新药和突破性疗法的问世，造福全球病患。”

作为创新的赋能者、客户信赖的合作伙伴以及全球健康产业的贡献者，药明康德和大多数客户一样，积极践行对可持续发展的承诺，并将其先进的理念融入到公司全球运营的方方面面，不断为社会和环境带来积极的影响。截至目前，公司已连续五年获得MSCI ESG领导力评级；连续四年入选道琼斯可持续发展指数（DJSI）；连续三年获得CDP气候变化“A-”级领导力评级、Morningstar Sustainalytics ESG“行业最高评级”及“区域最高评级”；首次获得MSCI ESG “AAA”最高评级、CDP水安全“A”级领导力评级、EcoVadis企业社会责任评级“金牌”认证。

此外，为进一步深化可持续发展承诺，药明康德持续拓展全球责任实践。公司温室气体减排近期目标成功通过了SBTi审核认证。同时，公司已加入联合国全球契约组织（UNGC），承诺支持全球契约十项原则；并加入制药供应链倡议（PSCI），成为PSCI供应商合作伙伴。

关于药明康德

药明康德（股票代码：603259.SH/2359.HK）是全球医药及生命科学行业值得信赖的合作伙伴和重要贡献者，致力于通过提供一体化、端到端的新药研发和生产服务，推动全球医药健康创新。公司在亚洲、欧洲、北美等地均设有运营基地，依托独特的“CRDMO”业务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来突破性的治疗方案。目前，公司的赋能平台正承载着来自全球30多个国家的约6,000家合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现“让天下没有难做的药，难治的病”的愿景。更多信息，请访问公司网站：www.wuxiapptec.com

WuXi AppTec Named Constituent of the FTSE4Good Index Series for Third Consecutive Year

SHANGHAI, August 5, 2025 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced its inclusion in the FTSE4Good Index Series for the third consecutive year. This recognition underscores the Company’s ongoing commitment to sustainable development and its efforts to build a healthier, more sustainable world.

Created by the global index and data provider FTSE Russell, the FTSE4Good Index Series is designed to measure the performance of companies demonstrating specific Environmental, Social and Governance (ESG) practices. Inclusion in the index is based on meeting specific ESG criteria. In the most-recent assessment cycle, WuXi AppTec achieved the highest score of 5 points in Corporate Governance, Anti-Corruption, and Labor Standards, reflecting the Company’s exemplary performance in sustainable management.

“We are honored to be recognized once again by FTSE Russell as a constituent of the FTSE4Good Index Series. This acknowledgement affirms the capital markets’ confidence in WuXi AppTec’s sustainable management practices,” said Dr. Steve Yang, Co-CEO of WuXi AppTec and Chairman of WuXi AppTec’s ESG Committee. “We remain committed to advancing our ESG initiatives while supporting our customers in bringing innovative new therapies to patients worldwide.”

As an enabler of innovation, a trusted partner, and a contributor to the global pharmaceutical and life sciences industry, WuXi AppTec strategically integrates sustainability like most of the customers into its global operations. The company’s ESG leadership has been recognized by several prestigious organizations: WuXi AppTec has received the MSCI ESG Leadership Rating for five consecutive years, has been included in the Dow Jones Sustainability Index (DJSI) for four consecutive years, and has earned an A- Leadership rating in the CDP Climate Change assessment for three consecutive years. Additionally, the Company has been recognized as an Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics, received its first MSCI ESG AAA rating, achieved an A Leadership rating in the CDP Water Security assessment, and was awarded a Gold Medal in the EcoVadis sustainability rating.

Furthering its sustainability commitments, WuXi AppTec has received Science Based Targets initiative (SBTi) validation for its near-term emissions reduction targets. The Company is also a participant in the United Nations Global Compact (UNGC), supporting its ten principles, and serves as a supplier partner to the Pharmaceutical Supply Chain Initiative (PSCI).

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at https://www.wuxiapptec.com.

免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。